Proteomic profiling of brain‐ and biofluid‐derived EVs has uncovered specific biomarkers and signaling pathways, ranging from tau and α‐synuclein in AD and PD to mutant SOD1 in ALS and complement activation in stroke and TBI. Here, MAPT is linked to Alzheimer disease.